Benedict Financial Advisors Inc. lessened its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 3.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,063 shares of the medical instruments supplier’s stock after selling 772 shares during the quarter. Becton Dickinson and comprises about 2.2% of Benedict Financial Advisors Inc.’s holdings, making the stock its 11th biggest holding. Benedict Financial Advisors Inc.’s holdings in Becton Dickinson and were worth $4,509,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Becton Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after purchasing an additional 1,353,780 shares in the last quarter. State Street Corp lifted its position in shares of Becton Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after purchasing an additional 342,873 shares in the last quarter. Northern Trust Corp lifted its position in shares of Becton Dickinson and by 4.0% during the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after purchasing an additional 106,966 shares in the last quarter. Fundsmith LLP lifted its position in shares of Becton Dickinson and by 0.3% during the second quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock worth $449,258,000 after purchasing an additional 5,977 shares in the last quarter. Finally, Mawer Investment Management Ltd. lifted its position in shares of Becton Dickinson and by 1.4% during the third quarter. Mawer Investment Management Ltd. now owns 1,799,828 shares of the medical instruments supplier’s stock worth $352,599,000 after purchasing an additional 24,761 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on BDX shares. Wells Fargo & Co reissued a “positive” rating and set a $235.00 price target (up previously from $225.00) on shares of Becton Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Argus increased their price target on shares of Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. KeyCorp started coverage on shares of Becton Dickinson and in a research report on Friday, January 5th. They set an “overweight” rating and a $260.00 price target on the stock. Bank of America reissued a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a research report on Friday, January 19th. Finally, Morgan Stanley increased their price target on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $237.27.

Shares of Becton Dickinson and Co (NYSE BDX) opened at $211.44 on Friday. The firm has a market cap of $60,575.49, a P/E ratio of 161.40, a P/E/G ratio of 1.62 and a beta of 1.12. Becton Dickinson and Co has a 1-year low of $175.66 and a 1-year high of $248.39. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 19.84%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.33 earnings per share. equities analysts forecast that Becton Dickinson and Co will post 10.94 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be issued a $0.75 dividend. The ex-dividend date is Thursday, March 8th. This represents a $3.00 annualized dividend and a yield of 1.42%. Becton Dickinson and’s dividend payout ratio (DPR) is 229.01%.

TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2018/02/09/benedict-financial-advisors-inc-trims-stake-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.